Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management

Table 1

Clinical trials of cytocidal anticancer drugs for elderly patients with NSCLC.

Study, author	.	Treatment	RR (%)	OS (month)	PFS (month)	Neutropenia; G3-4 (%)
Phase III trials
ELVIS [12]	78	VNR	19.7	6.5	NR	NR
	96	BSC	-	4.9	-	-
MILES [13]	232	VNR + GEM	21	7.6	4.8	18
	233	VNR	18	8.8	4.5	25
	233	GEM	16	6.6	4.3	8
WJTOG9904 [14]	88	DTX	22.7	14.3	5.5	82.9
	91	VNR	9.9	9.9	3.1	69.3
IFCT-0501 [15]	225	CBDCA + PTX	27.1	10.3	6	48.4
	226	VNR or GEM	10.2	6.2	2.8	12.4
MILES-3/MILES-4 [16]	263	CDDP + GEM or PEM	15.5	9.6	4.6	Significantly higher and more sever in CDDP group.
	268	GEM or PEM	8.5	7.5	3
JCOG0803 [17]	139	CDDP + DTX	34.4	14.8	4.7	10.1
	137	DTX	24.6	13.3	4.4	88.8
JCOG0207 [18]	63	CDDP + DTX	55	17	6.2	14.3
	63	DTX	26.2	10.7	3.7	4.8
Subset analysis of elderly group
Socinski et al. [19]	73	nab-PTX + CBDCA	34	8	19.9	55
	81	PTX + CBDCA	24	6.8	10.4	73
PARAMOUNT [20]	52	PEM	42	13.7	6.4	17
	40	Placebo	43	12.1	3	-

RR = response rate, OS = overall survival, PFS = progression free survival, NR = not reported, VNR = vinorelbine, BSC = best supportive care, GEM = gemcitabine, DTX = docetaxel, PTX = paclitaxel, CDDP = cisplatin, CBDCA = carboplatine, nab-PTX = nanoparticle albumin-bound paclitaxel, and PEM = pemetrexed.